43 research outputs found
Π‘ΠΈΡΡΠ΅ΠΌΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ»Π΅ΠΊΡΡΠΈΡΠ΅ΡΠΊΠΈΡ ΠΌΠ°ΡΠΈΠ½ Π² Π³ΠΎΡΠ½ΠΎΠ΄ΠΎΠ±ΡΠ²Π°ΡΡΠ΅ΠΌ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ΅
ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π° ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ»ΠΎΠ³ΠΈΡ, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡΠ°Ρ ΠΎΡΠ΅Π½ΠΈΡΡ ΠΈ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΡΠ½ΠΊΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ»Π΅ΠΊΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ°ΡΠΈΠ½ Ρ ΡΠΎΡΠΊΠΈ Π·ΡΠ΅Π½ΠΈΡ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°. ΠΡΠΎΠΈΠ·Π²Π΅Π΄Π΅Π½ΠΎ Π΄Π΅Π·Π°Π³ΡΠ΅Π³ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ΅Π»ΠΈ Π½Π° ΡΠΎΡΡΠ°Π²Π½ΡΠ΅ ΡΠ»Π΅ΠΌΠ΅Π½ΡΡ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΎΡΡΠ°ΠΆΠ΅Π½Ρ Π² Π²ΠΈΠ΄Π΅ Π΄Π΅ΡΠ΅Π²Π° ΡΠ΅Π»Π΅ΠΉ, ΡΡΠΎ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΠΈΠ·ΡΡΠΈΡΡ ΡΡΡΡΠΊΡΡΡΡ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½ΠΈΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠΊΡΠΏΠ»ΡΠ°ΡΠ°ΡΠΈΠΈ ΠΈ ΠΎΠ±ΡΠ»ΡΠΆΠΈΠ²Π°Π½ΠΈΡ ΡΠ»Π΅ΠΊΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ°ΡΠΈΠ½. ΠΠ° ΠΎΡΠ½ΠΎΠ²Π΅ ΡΠΊΡΠΏΠ΅ΡΡΠ½ΠΎΠΉ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Ρ ΠΊΠΎΡΡΡΠΈΡΠΈΠ΅Π½ΡΡ ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π²Π°ΠΆΠ½ΠΎΡΡΠΈ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΎΠ² Π΄Π΅ΡΠ΅Π²Π° ΡΠ΅Π»Π΅ΠΉ. ΠΠ΅ΡΠΎΠ΄ΠΎΠ»ΠΎΠ³ΠΈΡ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Π° Π΄Π»Ρ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΠΈ ΡΡΡΡΠΊΡΡΡΠΈΠ·Π°ΡΠΈΠΈ ΠΏΡΠΎΠ±Π»Π΅ΠΌ, ΡΠ²ΡΠ·Π°Π½Π½ΡΡ
Ρ ΡΠΊΡΠΏΠ»ΡΠ°ΡΠ°ΡΠΈΠ΅ΠΉ ΠΈ ΠΎΠ±ΡΠ»ΡΠΆΠΈΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΠ»Π΅ΠΊΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ°ΡΠΈΠ½
Treatment efficacy in a soman-poisoned guinea pig model: added value of physostigmine?
Current treatment of organophosphate poisoning is insufficient, and survivors may suffer from long-lasting adverse effects, such as cognitive deficits and sleep-wake disturbances. In the present study, we aimed at developing a guinea pig model to investigate the benefits of immediate and delayed stand-alone therapy on the development of clinical signs, EEG, heart rate, respiration and AChE activity in blood and brain after soman poisoning. The model allowed the determination of the therapeutic effects at the short-term of obidoxime, atropine and physostigmine. Obidoxime exerted the highest therapeutic efficacy at administration of the lowest dose (3.1Β mg/kg i.m.), whereas two higher doses (9 and 18Β mg/kg) were less effective on most parameters. Addition of atropine at 0.03 and 3Β mg/kg (i.m.) to the treatment did not improve the therapeutic effects of obidoxime alone. Physostigmine (0.8Β mg/kg im) at 1Β min after poisoning increased mortality. Two lower doses (0.1 and 0.3Β mg/kg i.m.) showed improvements on all parameters but respiration. The middle dose was most effective in preventing seizure development and therefore assessed as the most efficacious dose. Combined treatment of obidoxime and physostigmine shortened the duration of seizures, if present, from up to 80Β min to ~10β15Β min. In practice, treatment will be employed when toxic signs appear, with the presence of high levels of AChE inhibition in both blood and brain. Administration of physostigmine at that moment showed to be redundant or even harmful. Therefore, treatment of OP poisoning with a carbamate, such as physostigmine, should be carefully re-evaluated